Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- HER2: biology, detection, and clinical implications.Arch Pathol Lab Med. 2011; 135: 55-62
- Current and Future Management of HER2-Positive Metastatic Breast Cancer.JCO Oncol Pract. 2021; 17: 594-604
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.J Clin Oncol. 2018; 36: 2105-2122
- NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+.J Clin Oncol. 2020; 38: 444-453
- Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastat.J Clin Oncol. 2010; 28: 1131-1137
- HER2-Low Breast Cancer: Pathological and Clinical Landscape.J Clin Oncol. 2020; 38: 1951-1962
- Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.Clin Cancer Res. 2005; 11 (Available at:): 865s-870s
- Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.npj Breast Cancer. 2021; 7: 1
- Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.Lancet Oncol. 2021; 22: 1151-1161
- Evolution of HER2-low expression from primary to recurrent breast cancer.npj Breast Cancer. 2021; 7: 137
- HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.Cancers (Basel). 2021; 13: 2824
- Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.Breast Cancer Res. 2022; 24: 22
- HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.BMC Med. 2022; 20: 105
- 1MO - Prognostic and biologic significance of HER2-low expression in early breast cancer.Ann Oncol. 2022; 33: S124
- 291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting.Ann Oncol. 2021; 32: S491
- Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.Eur J Cancer. 2021; 155: 1-12
- Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.Breast Cancer Res. 2021; 23: 112
- Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer.Am J Clin Pathol. 2013; 140: 561-566
- Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.JAMA Oncol. 2022; 8: 1
- Evolution of low HER2 expression between early and advanced-stage breast cancer.Eur J Cancer. 2022; 163: 35-43
- HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.npj Breast Cancer. 2022; 8: 66
- HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer.N Engl J Med. 2008; 358: 1409-1411
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831.J Clin Oncol. 2014; 32: 3744-3752
- First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.Ann Oncol. 2017; 28: 855-861
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine.J Clin Oncol. 2012; 30: 3234-3241
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy.J Clin Oncol. 2011; 29: 398-405
- Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.J Clin Oncol. 2020; 38: 502
- Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a ret.Anticancer Drugs. 2020; 31: 973-978
- Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.Cancer Discov. 2021; 11: 2474-2487
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study.J Clin Oncol. 2020; 19: 02318
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.N Engl J Med. 2022; 387: 9-20
- Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY).Cancer Res. 2022; 82: PD8-02
- Combining Antibody-drug Conjugates with Immunotherapy in Solid Tumors: Current Landscape and Future Perspectives.Cancer Treat Rev. 2022; 106: 102395
- A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model.Mol Cancer Ther. 2018; 17: 1494-1503
- BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).J Clin Oncol. 2021; 39: 1023
- 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer.Ann Oncol. 2022; 33: S196
- The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.Mol Cancer Ther. 2015; 14: 692-703
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.Lancet Oncol. 2019; 20: 1124-1135
- RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.J Clin Oncol. 2021; 39: 1022
- Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).J Clin Oncol. 2020; 38: 1037
- Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers.Ann Oncol. 2018; 29 (suppl 8; abstr 1147P): viii400-viii441
- Abstract P3-14-21: Phase II Study of Single Agent Trifunctional Antibody Ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 Low Expressing Hormone-Refractory Advanced Breast Cancer Patients (ABC).in: Poster session abstracts. American Association for Cancer Research, 2010: 14-21https://doi.org/10.1158/0008-5472.SABCS10-P3-14-21
- Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.J Clin Oncol. 2018; 36: 2500
- Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.Ann Oncol. 2014; 25: 1735-1742
- Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.Clin Cancer Res. 2019; 25: 4248-4254
- Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.Cancer Res. 2017; 77: 5374-5383
- Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.Clin Cancer Res. 2020; 26: 2515-2523
- Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.Breast Cancer Res Treat. 2020; 181: 391-401
- Unlocking the potential of antibody–drug conjugates for cancer therapy.Nat Rev Clin Oncol. 2021; 18: 327-344
- Bystander effect of antibody–drug conjugates: fact or fiction?.Curr Oncol Rep. 2022; 24: 809-817
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med. 2021; 384: 1529-1541
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
